Donepezil Hydrochloride (3bfe818b 5567 4e5d 8204 1db3190c7169 01)
Donepezil Hydrochloride Tablet
Product Images NDC 68180-527
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68180-527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (3bfe818b 5567 4e5d 8204 1db3190c7169 02)
Figure 2 (3bfe818b 5567 4e5d 8204 1db3190c7169 03)
This document seems to be a chart or graph displaying the cumulative percentage of patients in different treatment groups, with different dosages of Donepezil Hydrochloride and a placebo, and their corresponding change in ADAS-cog scores from baseline. The ADAS-cog is a metric used to measure cognitive function in patients with Alzheimer's disease. The chart appears to show that the group receiving the highest dose of donepezil (10 mg/day) experienced the smallest change in ADAS-cog scores from baseline, while the placebo group had the largest change in scores.*
Figure 3 (3bfe818b 5567 4e5d 8204 1db3190c7169 04)
This is a clinical trial report that compares the effectiveness of two different dosages of Donepezil Hydrochloride (10 mg/day vs. 5 mg/day) with a placebo in treating patients. The report indicates that the trial measures improvement in patients using the CIBIC-plus Rating scale, which evaluates for changes in cognitive abilities. However, the report does not provide any specifics on the results obtained from the trial.*
Figure 4 (3bfe818b 5567 4e5d 8204 1db3190c7169 05)
Figure 5 (3bfe818b 5567 4e5d 8204 1db3190c7169 06)
This appears to be a chart showing the cumulative percentage of patients based on their scores in a study, likely related to a treatment for Alzheimer's disease. The treatment options mentioned include a 10mg/day dose of Donepezil Hydrochloride, a 5mg/day dose of Donepezil Hydrochloride, and a placebo. There is also a column showing the change in ADAS-c09 scores with a percentage change of 74%, as well as some points indicating change from baseline. More specific information regarding the study and its findings cannot be determined from this text.*
Figure 6 (3bfe818b 5567 4e5d 8204 1db3190c7169 07)
This is a table showing the percentage of patients who have marked changes when administered with Donepezil Hydrochloride 10 mg/day or 5 mg/day, or a placebo, as measured by the CIBIC-plus Rating. The categories for change are "Markedly improved," "Moderately improved," "Minimally improved," "No change," "Minimally worse," "Moderately worse," and "Markedly worse."*
Figure 7 (3bfe818b 5567 4e5d 8204 1db3190c7169 08)
Figure 8 (3bfe818b 5567 4e5d 8204 1db3190c7169 09)
Figure 9 (3bfe818b 5567 4e5d 8204 1db3190c7169 10)
This is a description of a clinical trial in which the effects of Donepezil hydrochloride and a placebo on patients were evaluated. The text indicates that clinical improvement was observed in the group that received Donepezil hydrochloride, which increased over 3 months of drug treatment, while placebo led to a decline in clinical improvement. The description also indicates that a baseline was established at the start of the trial.*
Figure 10 (3bfe818b 5567 4e5d 8204 1db3190c7169 11)
Figure 11 (3bfe818b 5567 4e5d 8204 1db3190c7169 12)
This is a clinical study that involved treatment with Donepezil Hydrochloride at 23 mg/day and 10 mg/day dosages for an unspecified condition. The study lasted for weeks, and it showed notable improvements in clinical outcomes.*
Figure 12 (3bfe818b 5567 4e5d 8204 1db3190c7169 13)
Figure 13 (3bfe818b 5567 4e5d 8204 1db3190c7169 14)
This text appears to be a chart with medication dosage and a rating scale for patients taking Donepezil Hydrochloride. The chart details the percentage of patients whose condition improved or worsened, and the extent of the change from minimal to marked. The CIBIC-plus rating may be a method of assessing the effectiveness of the medication.*
Donepezil Hydrochloride Tabletsrx Only23 mgndc 68180-527-06 30 Tablets (3bfe818b 5567 4e5d 8204 1db3190c7169 15)
This is a medicine label for Donepezil Hydrochloride tablets. It contains instructions for storage (protect from moisture) and dosage (30 tablets). The label also includes the name and strength of the medication, as well as the name and address of the manufacturer (Lupin). The prescription must be dispensed by a pharmacist and should be accompanied by a patient's prescription note.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
